<DOC>
	<DOCNO>NCT02336178</DOCNO>
	<brief_summary>The purpose post-approval study evaluate safety efficacy Benefix subject hemophilia B usual care setting China .</brief_summary>
	<brief_title>Safety Efficacy Benefix Patients With Hemophilia B Usual Care Settings China</brief_title>
	<detailed_description>The purpose post-approval study provide supplementary information relate use BeneFIX Chinese subject hemophilia B , especially safety efficacy different population Chinese hemophilia B patient , particular pediatric patient &lt; 6 year age , pediatric patient ≥6 ≤12 year age , Previously Untreated Patients ( PUPs ) , subject receive prophylaxis treatment enrollment study , severe patient ( FIX activity &lt; 1 % ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male and/or female subject hemophilia B. Subjects/parents/legal representative must able comply study procedure ( informed consent/assent process , clinical visit , report infusion bleed data , report adverse event , etc ) Presence bleed disorder addition hemophilia B . Subjects past history , current factor IX inhibitor . For laboratorybased assessment , Bethesda inhibitor titer great laboratory 's normal range ≥0.6 Bethesda Unit ( BU ) /mL . Subjects know hypersensitivity active substance excipients BeneFIX . Subjects know hypersensitivity Chinese Hamster Ovary cell protein .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>